Allergy and Asthma Consultants of Wichita, KS Report issue

Academic/Hospital Phase 1

Organization Overview

First Clinical Trial
2014
NCT02235844
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Alternative names

Allergy and Asthma Consultants, Wichita, Kansas

Active Ingredients

Drugs in Phase 1 Trials (1)

umbilical cord mesenchymal stem cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Muscular Dystrophies (Phase 1)

Muscular Dystrophy, Duchenne (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1